Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma (Q24597152)

21

0 references

Antoni Ribas

33

0 references

Igor Puzanov

31

0 references

Grant McArthur

Grant A McArthur

34

0 references

Katherine L Nathanson

Katherine L Nathanson

39

0 references

Rafe Shellooe

16

Rafe Shellooe

0 references

Gideon Bollag

1

Gideon Bollag

0 references

Gaston Habets

10

Gaston Habets

0 references

Keith Flaherty

37

Keith T Flaherty

0 references

Chao Zhang

8

Chao Zhang

0 references

Keith Nolop

40

Keith Nolop

0 references

Jeffrey A Sosman

35

Jeffrey A Sosman

0 references

author name string

Peter Hirth

2

0 references

James Tsai

3

0 references

Jiazhong Zhang

4

0 references

Prabha N Ibrahim

5

0 references

Hanna Cho

6

0 references

Wayne Spevak

7

0 references

Ying Zhang

9

0 references

Elizabeth A Burton

11

0 references

Bernice Wong

12

0 references

Garson Tsang

13

0 references

Brian L West

14

0 references

Ben Powell

15

0 references

Adhirai Marimuthu

17

0 references

Hoa Nguyen

18

0 references

Kam Y J Zhang

19

0 references

Dean R Artis

20

0 references

Fei Su

22

0 references

Brian Higgins

23

0 references

Raman Iyer

24

0 references

Kurt D'Andrea

25

0 references

Astrid Koehler

26

0 references

Michael Stumm

27

0 references

Paul S Lin

28

0 references

Richard J Lee

29

0 references

Joseph Grippo

30

0 references

Kevin B Kim

32

0 references

Paul B Chapman

36

0 references

Xiaowei Xu

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

38

0 references

language of work or name

English

0 references

publication date

30 September 2010

0 references

published in

Nature

0 references

volume

467

0 references

issue

7315

0 references

page(s)

596-9

0 references

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2948082

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

24 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2948082

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

24 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2948082

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

24 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2948082

Mutations of the BRAF gene in human cancer

24 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2948082

A dimerization-dependent mechanism drives RAF catalytic activation

24 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2948082

Uncoupling of the LKB1-AMPKalpha energy sensor pathway by growth factors and oncogenic BRAF

24 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2948082

Patterns of somatic mutation in human cancer genomes

24 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2948082

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2948082

BRAF mutation predicts sensitivity to MEK inhibition

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2948082

Coordinating ERK/MAPK signalling through scaffolds and inhibitors

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2948082

BRAFE600-associated senescence-like cell cycle arrest of human naevi

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2948082

Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032.

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2948082

RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2948082

Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2948082

(V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2948082

Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2948082

Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2948082

Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2948082

Keratoacanthomas associated with sorafenib therapy

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2948082

Regulation of Raf-1 by direct feedback phosphorylation.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2948082

Technology platforms for pharmacogenomic diagnostic assays

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2948082

High frequency of BRAF mutations in nevi

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2948082

Paradoxical activation of Raf by a novel Raf inhibitor

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2948082

Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2948082

A negative feedback signaling network underlies oncogene-induced senescence

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2948082

Randomized phase II trial evaluating two paclitaxel and cisplatin-containing chemoradiation regimens as adjuvant therapy in resected gastric cancer (RTOG-0114).

28 November 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FNATURE09454

inferred from DOI database lookup

7 January 2021

based on heuristic

Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FNATURE09454

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/NATURE09454

1 reference

Dimensions Publication ID

1032620847

0 references

1 reference

1 reference

PubMed publication ID

20823850

1 reference